Format: 10 mg cagrilintide + 10 mg GLP-3 (RT) · Purity: ≥99% by reverse-phase HPLC · Identity: ESI-MS confirmed
Cagri-Reta pairs two of the most-studied metabolic peptides in one vial: cagrilintide, a long-acting amylin analog, and GLP-3 (RT), a triple GLP-1/GIP/glucagon receptor agonist. Combining them lets researchers look at amylin signaling and triple incretin-receptor signaling in the same preparation. This vial contains 10 mg of each peptide, supplied for metabolic research.
Structure & Identity
Cagri-Reta is a combination of two separate peptides rather than a single molecule. Cagrilintide acts at amylin and calcitonin receptors, while GLP-3 (RT) is engineered to activate the GLP-1, GIP, and glucagon receptors. Each retains its own structure and targets; the product simply brings both into one vial for combined research. Note that GLP-3 (RT) is a GLP-1/GIP/glucagon agonist, not a GLP-3 agonist.
Research Background
Cagri-Reta research explores amylin signaling combined with triple incretin-receptor signaling.
- Combined approach. Cagri-Reta joins amylin signaling (cagrilintide) with triple GLP-1/GIP/glucagon signaling (retatrutide) [PMID: 34288673].
- Amylin basis. The cagrilintide component rests on its development as a long-acting amylin analog [PMID: 34288673].
- Triple-agonist basis. The retatrutide component is characterized as a GLP-1/GIP/glucagon triple agonist [PMID: 37366315].
- Amylin class. Amylin analogs are an active metabolic-research area [PMID: 39317404].
- Receptor research. Retatrutide’s three-receptor activity is documented [PMID: 42250575].
These are research contexts, not approved uses, and the combination is intended for laboratory study.
Specifications
| Attribute |
Value |
| Product type |
Combination (two peptides) |
| Component 1 |
Cagrilintide (amylin analog), 10 mg |
| Component 2 |
GLP-3 (RT) (GLP-1/GIP/glucagon agonist), 10 mg |
| Total quantity |
20 mg per vial (10 mg + 10 mg) |
| Purity |
≥99% by reverse-phase HPLC (each component) |
| Length |
2 peptides (amylin analog + triple agonist) |
| Identity |
Confirmed by ESI mass spectrometry |
| Physical form |
Lyophilized powder |
| Appearance |
White to off-white solid |
| Storage |
-20°C, protected from light |
| Solubility |
Soluble in bacteriostatic or sterile water (gentle mixing) |
| Classification |
Research use only |
Storage & Handling
Store the sealed vial frozen at -20°C, shielded from light, until use. After reconstitution, keep the solution refrigerated at 2-8°C and use it within about two weeks. With an amylin-type peptide among the components, gentle reconstitution, warming to room temperature before opening, and minimal freeze-thaw cycles all help protect the material.
Storage and Handling Guide
Quality Assurance
The components of Cagri-Reta are produced under research-grade manufacturing controls and verified by an independent lab before release. Purity is measured by reverse-phase HPLC and identity by mass spectrometry, with testing carried out by third-party laboratories such as Janoshik Analytical along with domestic US labs. A certificate of analysis is published for each batch, so the results reflect the production lot you receive.
Quality & Testing
Frequently Asked Questions
What is Cagri-Reta?
Cagri-Reta is a combination research product containing cagrilintide (an amylin analog) and GLP-3 (RT) (a triple GLP-1/GIP/glucagon receptor agonist), 10 mg of each. It is studied in metabolic research and supplied for research use only.
Why combine cagrilintide with GLP-3 (RT)?
It brings together amylin signaling and triple incretin-receptor signaling in one preparation, letting researchers study the two complementary approaches side by side.
Are the two peptides fused together?
No, they are two separate molecules combined in a single vial, each with its own structure and receptor targets. Cagri-Reta is a mixture, not a single fused peptide.
How much of each peptide is in the vial?
There is 10 mg of cagrilintide and 10 mg of GLP-3 (RT), for 20 mg of peptide total.
Is Cagri-Reta FDA approved?
No, neither component combination is FDA approved. The material here is a research-use-only preparation, not for human or veterinary use.
Does GLP-3 (RT) target a GLP-3 receptor?
No, GLP-3 (RT) is a GLP-1/GIP/glucagon triple agonist; there is no GLP-3 receptor. The label sometimes shortens this incorrectly.
How should Cagri-Reta be stored?
Keep the powder frozen at -20°C and protected from light. Once reconstituted for research, store at 2-8°C and use within about two weeks.
How are both components verified?
Each is tested to ≥99% purity by reverse-phase HPLC with mass-spec identity confirmation by an independent lab, and each batch has a published certificate of analysis.
References
- Development of Cagrilintide, a Long-Acting Amylin Analogue. 2021. PMID: 34288673.
- Triple-Hormone-Receptor Agonist GLP-3 (RT) for Obesity – A Phase 2 Trial. 2023. PMID: 37366315.
- Amylin analogs for the treatment of obesity without diabetes: present and future. 2024. PMID: 39317404.
